Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
CH:IDIA
Stock Latest News
Ratings
Idorsia: Leadership Reset and Pipeline Expansion Underpin Buy Rating and CHF5 Price Target
4d ago
Premium
Ratings
Idorsia: Expanding QUVIVIQ Footprint and Aprocitentan Upside Support Buy Rating Despite Lowered Target
9d ago
Premium
The Fly
Idorsia price target lowered to CHF 5 from CHF 6 at H.C. Wainwright
9d ago
Premium
Company Announcements
Idorsia Earnings Call Signals Turnaround, Risks Linger
24d ago
Premium
Ratings
Idorsia: FDA-Aligned Phase 3 Pathway and Broad Fabry Disease Positioning Support Buy Rating and CHF6 Target
1M ago
Premium
Ratings
Idorsia: Latin America QUVIVIQ Deal and Pipeline Optionality De‑Risk Path to Profitability, Supporting Reiterated Buy Rating
2M ago
Premium
Ratings
Idorsia: Differentiated Insomnia and Hypertension Assets, Understated Guidance, and Pipeline Upside Support Reiterated Buy Rating
2M ago
Premium
Ratings
Idorsia: Cardiovascular Franchise Momentum and Underappreciated Pipeline Drive Buy Rating and Valuation Upside
3M ago
Premium
Ratings
Buy Rating for Idorsia Driven by Promising Aprocitentan Trial Results and Market Potential
3M ago
Premium
The Fly
Idorsia upgraded to Buy from Hold at Kepler Cheuvreux
4M ago
Premium
Ratings
Idorsia Ltd’s Strengthened Financial Position and Growth Prospects Justify Buy Rating
5M ago
Premium
Ratings
Idorsia’s Growth Potential Bolstered by Aprocitentan Approval and Strategic Commercialization Efforts
6M ago
Premium
The Fly
Idorsia upgraded to Buy from Neutral at H.C. Wainwright
6M ago
Premium
The Fly
Idorsia price target raised to CHF 2 from CHF 1 at Deutsche Bank
7M ago
Premium
Company Announcements
Idorsia Ltd Earnings Call: Strong Growth Amid Challenges
8M ago
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
